AVANT to Present at the BIO 2003 Annual Convention
NEEDHAM, Mass., Jun 19, 2003 (BUSINESS WIRE) -- AVANT Immunotherapeutics, Inc. (AVAN) announced today that it will participate in several presentations showcasing AVANT's biodefense and other vaccine strategies next week at the BIO 2003 Annual Convention in Washington, D.C., June 22-25.
Included will be a Business Forum presentation where AVANT President and Chief Executive Officer, Dr. Una Ryan, will provide an overview of AVANT's programs on Tuesday, June 24, at 3:00 P.M. Eastern Time. This presentation will be available as live webcast, with replays available for approximately four weeks, through the investor information section of AVANT's website (www.avantimmune.com) or through the conference website run by BIO (www.bio.org).
Dr Ryan will also participate in a Media Brunch on Sunday June 22 addressing Global Health Issues. On Tuesday, June 24, Dr. Ryan will present on Capitol Hill in a discussion entitled, "Creating a BioDefense Industry: Whether, How, What and When?" A similar panel discussion will occur on Wednesday, June 25 at the Washington Convention Center.
In addition, Dr. Kevin Killeen, Senior Director, Bacterial Vaccines, at AVANT, will chair a panel discussion entitled, "When is a Vaccine Safe Enough: Rotavirus vaccines as a Case Study" on Monday, June 23 at the Washington Convention Center.
About BIO
The Biotechnology Industry Organization (BIO) represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products. Dr. Ryan is a member of the Board of Directors of BIO.
About AVANT
AVANT Immunotherapeutics, Inc. is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. The company is developing a broad portfolio of vaccines addressing a wide range of applications including bacterial and viral diseases, chronic human disease, biodefense and food safety. These include single-dose, oral vaccines that protect against important disease-causing agents and a novel, proprietary vaccine candidate for cholesterol management. AVANT's goal is to demonstrate proof-of-concept for its products before leveraging their value through partnerships. Current collaborations encompass the development of an oral human rotavirus vaccine, vaccines to combat threats of biological warfare, and vaccines addressed to human food safety and animal health.
Additional information on AVANT Immunotherapeutics, Inc. can be obtained through our site on the World Wide Web: avantimmune.com.
SOURCE: AVANT Immunotherapeutics, Inc. AVANT Immunotherapeutics,
AVANT Immunotherapeutics, Inc.Una S. Ryan, Ph.D., 781/433-0771orAVANT Immunotherapeutics, Inc.Avery W. Catlin, 781/433-0771info@avantimmune.comorFor Media:Kureczka/Martin AssociatesJoan Kureczka, 415/821-2413jkureczka@aol.com |
